The choice of first line therapy differs on tumor sidedness. Professor Alan P. Venook, MD, joins us from the 2018 Gastrointestinal Cancers Symposium and talks about the deciding factor when it comes to the first line of therapy for either left-sided or right-sided patients.
Using EGFR Antibodies as a First Line Therapy Depending on Tumor Sidedness
